March 21st 2023
By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.
Vitiligo Repigmentation Improvements More Noticeable in Patient-Reported Outcome Measures
October 13th 2022Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
Thyroid Abnormalities Rare Among Children with Vitiligo, Study Finds
September 30th 2022The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.
Improvements in Vitiligo Repigmentation More Noticeable in Patient-Reported Outcome Measures
September 8th 2022Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
How Ruxolitinib Will Change the Future of Vitiligo Treatment
July 21st 2022Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.